A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Breast Cancer
Unresectable Breast Carcinoma
Metastatic Breast Cancer

Interventions

DRUG: BNT323
DRUG: BNT327

Sponsor

BioNTech SE

Collaborators

[object Object]
[object Object]